Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you offer an adjuvant aromatase inhibitor following capecitabine to a post menopausal patient with ER 0%/PR 5%/HER2 0 with poor tolerance to neoadjuvant chemotherapy with residual ypT2N0M0?
Related Questions
Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
Would you discontinue tamoxifen for endometrial hyperplasia without dysplasia in the adjuvant setting?
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?
How would you treat a patient with bilateral breast cancer, HER2 positive on one side and HER2 negative on the contralateral side, specifically in regards to adjuvant CDK4/6i vs neratinib?
What are your top takeaways in Breast Cancer from ASCO 2025?
